|

Sapu003 Clinical Trials

1 actively recruiting trial

Also known as: Sapu003/Everolimus for Injection

Pipeline

Phase 1: 1

Top Sponsors

  • SAPU NANO (US) LLC1

Indications

  • Liver Disease1
  • Tuberous Sclerosis Complex (TSC)1
  • Multiple Sclerosis1
  • Renal Cell Carcinoma (RCC)1
  • Hepatocellular Carcinoma (HCC)1

Other1 trial

Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.